Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 218

1.

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.

Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, Rettie AE.

JAMA. 2002 Apr 3;287(13):1690-8.

PMID:
11926893
3.
4.

Influence of warfarin dose-associated genotypes on the risk of hemorrhagic complications in Chinese patients on warfarin.

Ma C, Zhang Y, Xu Q, Yang J, Zhang Y, Gao L, Xu B, Wang H, Li Y, Lu C, Yin T.

Int J Hematol. 2012 Dec;96(6):719-28. doi: 10.1007/s12185-012-1205-8.

PMID:
23104259
5.

Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy.

Limdi NA, Wiener H, Goldstein JA, Acton RT, Beasley TM.

Blood Cells Mol Dis. 2009 Jul-Aug;43(1):119-28. doi: 10.1016/j.bcmd.2009.01.019.

6.

VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.

Shaw K, Amstutz U, Hildebrand C, Rassekh SR, Hosking M, Neville K, Leeder JS, Hayden MR, Ross CJ, Carleton BC.

Pediatr Blood Cancer. 2014 Jun;61(6):1055-62. doi: 10.1002/pbc.24932.

PMID:
24474498
7.

Association between the CYP2C9 polymorphism and the drug metabolism phenotype.

Topić E, Stefanović M, Samardzija M.

Clin Chem Lab Med. 2004 Jan;42(1):72-8.

PMID:
15061384
8.

Gene-based warfarin dosing compared with standard of care practices in an orthopedic surgery population: a prospective, parallel cohort study.

McMillin GA, Melis R, Wilson A, Strong MB, Wanner NA, Vinik RG, Peters CL, Pendleton RC.

Ther Drug Monit. 2010 Jun;32(3):338-45. doi: 10.1097/FTD.0b013e3181d925bb.

PMID:
20386359
9.

An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.

Meckley LM, Wittkowsky AK, Rieder MJ, Rettie AE, Veenstra DL.

Thromb Haemost. 2008 Aug;100(2):229-39.

PMID:
18690342
10.

The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon.

Visser LE, van Schaik RH, van Vliet M, Trienekens PH, De Smet PA, Vulto AG, Hofman A, van Duijn CM, Stricker BH.

Thromb Haemost. 2004 Jul;92(1):61-6.

PMID:
15213846
11.

Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates.

Lund K, Gaffney D, Spooner R, Etherington AM, Tansey P, Tait RC.

Br J Haematol. 2012 Jul;158(2):256-61. doi: 10.1111/j.1365-2141.2012.09150.x.

PMID:
22571356
12.

Pharmacogenetics of warfarin elimination and its clinical implications.

Takahashi H, Echizen H.

Clin Pharmacokinet. 2001;40(8):587-603. Review.

PMID:
11523725
13.

Genetic modulation of oral anticoagulation with warfarin.

Margaglione M, Colaizzo D, D'Andrea G, Brancaccio V, Ciampa A, Grandone E, Di Minno G.

Thromb Haemost. 2000 Nov;84(5):775-8.

PMID:
11127854
14.

CYP2C9 genotypes and the quality of anticoagulation control with warfarin therapy among Brazilian patients.

Lima MV, Ribeiro GS, Mesquita ET, Victer PR, Vianna-Jorge R.

Eur J Clin Pharmacol. 2008 Jan;64(1):9-15.

PMID:
17955230
15.

The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin.

Tabrizi AR, Zehnbauer BA, Borecki IB, McGrath SD, Buchman TG, Freeman BD.

J Am Coll Surg. 2002 Mar;194(3):267-73.

PMID:
11893129
16.

VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation.

Schalekamp T, Brassé BP, Roijers JF, Chahid Y, van Geest-Daalderop JH, de Vries-Goldschmeding H, van Wijk EM, Egberts AC, de Boer A.

Clin Pharmacol Ther. 2006 Jul;80(1):13-22.

PMID:
16815313
17.

CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy.

Peyvandi F, Spreafico M, Siboni SM, Moia M, Mannucci PM.

Clin Pharmacol Ther. 2004 Mar;75(3):198-203.

PMID:
15001971
18.

The influence of VKORC1 and CYP2C9 gene sequence variants on the stability of maintenance phase warfarin treatment.

Skov J, Bladbjerg EM, Leppin A, Jespersen J.

Thromb Res. 2013 Feb;131(2):125-9. doi: 10.1016/j.thromres.2012.11.004.

PMID:
23159229
19.

Association of gene polymorphisms with the risk of warfarin bleeding complications at therapeutic INR in patients with mechanical cardiac valves.

An SH, Lee KE, Chang BC, Gwak HS.

J Clin Pharm Ther. 2014 Jun;39(3):314-8. doi: 10.1111/jcpt.12143.

PMID:
24602049
20.

Determination of bleeding risk using genetic markers in patients taking phenprocoumon.

Hummers-Pradier E, Hess S, Adham IM, Papke T, Pieske B, Kochen MM.

Eur J Clin Pharmacol. 2003 Jul;59(3):213-9.

PMID:
12728288
Items per page

Supplemental Content

Support Center